Gankyrin: a novel promising therapeutic target for hepatocellular carcinoma
Source abstract
Abstract
Hepatocellular carcinoma (HCC) is known as fifth common malignancies and third common cause of cancer-related death worldwide. The identification of various mechanisms which are involved in hepatocarcinogenesis contributes in finding a variety of cellular and molecular targets for HCC diagnosis, prevention and therapy. Among various identified targets in HCC pathogenesis, Gankyrin is a crucial oncoprotein that is up-regulated in HCC and plays a pivotal role in the initiation and progression of the HCC. Oncogenic role of Gankyrin has been found to stem from inhibition of two ubiquitous tumour suppressor proteins, retinoblastoma protein (pRb) and P53, and also modulation of several vital cellular signalling pathways including Wnt/β-Catenin, NF-κB, STAT3/Akt, IL-1β/IRAK-1 and RhoA/ROCK. As a result, Gankyrin can be considered as a potential candidate for diagnosis and treatment of HCC. In this review, we summarized the physiological function and the significant role of Gankyrin as an important therapeutic target in HCC.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Ubiquitin and proteasome pathways · Autophagy in Disease and Therapy · Endoplasmic Reticulum Stress and Disease
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Medical Biotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran;
Nanotechnology Research Center, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran;
Department of Medical Biotechnology, Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran;
Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
Funding
Mashhad University of Medical Sciences
References (100+)
Show source-provided references
1. 10.3322/caac.2010710.3322/caac.20107 ↗
2. Davis GL, Dempster J, Meler JD, et al. Hepatocellular carcinoma: management of an increasingly common problem. Proceedings. Dallas, TX: Baylor University Medical Center; 2008.10.1080/08998280.2008.11928410 ↗
3. 10.2174/138161282266616030311083810.2174/1381612822666160303110838 ↗
4. 10.1097/MCG.0b013e3182872f2910.1097/MCG.0b013e3182872f29 ↗
5. 10.3748/wjg.v19.i37.614410.3748/wjg.v19.i37.6144 ↗
6. Terry K, Copur MS. Molecular targeted therapy of hepatocellular carcinoma. J Cancer Ther. 2013;4:426–439.10.4236/jct.2013.42A052 ↗
7. 10.1016/j.bbadis.2008.08.00310.1016/j.bbadis.2008.08.003 ↗
8. 10.1007/s00535-003-1141-810.1007/s00535-003-1141-8 ↗
9. 10.1038/7160010.1038/71600 ↗
10. 10.1074/jbc.M31026520010.1074/jbc.M310265200 ↗
11. 10.1021/bi049116o10.1021/bi049116o ↗
12. 10.1021/bi011550s10.1021/bi011550s ↗
13. Jing H · Sci Rep · 2014 · 4
14. Li J · Curr Chem Biol · 2010 · 4 · 13
15. 10.1021/bi00151a03510.1021/bi00151a035 ↗
16. 10.1016/S0378-1119(98)00309-610.1016/S0378-1119(98)00309-6 ↗
17. 10.1016/j.ccr.2005.06.00610.1016/j.ccr.2005.06.006 ↗
18. 10.1016/S1097-2765(00)80042-810.1016/S1097-2765(00)80042-8 ↗
19. 10.1110/ps.0355460410.1110/ps.03554604 ↗
20. 10.1021/bi062188q10.1021/bi062188q ↗
21. 10.1016/j.canlet.2010.04.01910.1016/j.canlet.2010.04.019 ↗
22. 10.1172/JCI4254210.1172/JCI42542 ↗
23. 10.1016/j.prp.2015.09.01010.1016/j.prp.2015.09.010 ↗
24. 10.1371/journal.pone.009504310.1371/journal.pone.0095043 ↗
25. 10.1016/j.yexmp.2012.12.00210.1016/j.yexmp.2012.12.002 ↗
26. 10.1038/onc.2012.35610.1038/onc.2012.356 ↗
27. 10.3892/mmr.2013.186010.3892/mmr.2013.1860 ↗
28. 10.1158/0008-5472.CAN-12-458610.1158/0008-5472.CAN-12-4586 ↗
29. 10.4161/cbt.9.2.1028310.4161/cbt.9.2.10283 ↗
30. 10.1002/ijc.2310610.1002/ijc.23106 ↗
31. 10.1002/hep.2670510.1002/hep.26705 ↗
32. 10.18632/oncotarget.404310.18632/oncotarget.4043 ↗
33. 10.1134/S002689331401018X10.1134/S002689331401018X ↗
34. 10.1186/1477-7819-10-16910.1186/1477-7819-10-169 ↗
35. Li J · Anticancer Res · 2011 · 31 · 2683
36. 10.1134/S002689331006006310.1134/S0026893310060063 ↗
37. 10.3109/00016489.2013.84436210.3109/00016489.2013.844362 ↗
38. 10.1016/j.canlet.2012.10.03710.1016/j.canlet.2012.10.037 ↗
39. 10.1111/iju.1248410.1111/iju.12484 ↗
40. 10.18632/oncotarget.237510.18632/oncotarget.2375 ↗
41. Chen J · Oncogene · 2015
42. 10.4149/neo_2017_51110.4149/neo_2017_511 ↗
43. Wang C · Invest New Drugs
44. 10.1007/s13277-016-4854-z10.1007/s13277-016-4854-z ↗
45. 10.3748/wjg.v8.i4.63810.3748/wjg.v8.i4.638 ↗
46. 10.1002/hep.2401510.1002/hep.24015 ↗
47. 10.1002/hep.2202710.1002/hep.22027 ↗
48. 10.1016/S1471-4914(02)02317-110.1016/S1471-4914(02)02317-1 ↗
49. 10.1073/pnas.94.9.427310.1073/pnas.94.9.4273 ↗
50. 10.4161/cc.4.10.210710.4161/cc.4.10.2107 ↗
51. 10.4161/cc.5.5.251510.4161/cc.5.5.2515 ↗
52. 10.1016/j.ccr.2005.06.01410.1016/j.ccr.2005.06.014 ↗
53. 10.1038/onc.2008.4310.1038/onc.2008.43 ↗
54. 10.1016/j.molcel.2005.10.01710.1016/j.molcel.2005.10.017 ↗
55. 10.1038/cr.2007.9910.1038/cr.2007.99 ↗
56. 10.1186/1476-4598-12-11410.1186/1476-4598-12-114 ↗
57. 10.1038/cr.2011.10310.1038/cr.2011.103 ↗
58. 10.1002/hep.2755110.1002/hep.27551 ↗
59. 10.1038/nature0331910.1038/nature03319 ↗
60. 10.1038/ncb0402-e10110.1038/ncb0402-e101 ↗
61. 10.1038/3507721910.1038/35077219 ↗
62. 10.1126/science.109429110.1126/science.1094291 ↗
63. 10.1016/S0960-9822(06)00046-710.1016/S0960-9822(06)00046-7 ↗
64. 10.1038/sj.onc.120994210.1038/sj.onc.1209942 ↗
65. 10.1136/ard.2004.02826610.1136/ard.2004.028266 ↗
66. 10.1016/j.ccr.2006.12.01610.1016/j.ccr.2006.12.016 ↗
67. 10.1016/j.cell.2005.04.01410.1016/j.cell.2005.04.014 ↗
68. 10.1016/j.bbrc.2007.09.07210.1016/j.bbrc.2007.09.072 ↗
69. 10.1016/S0092-8674(02)00703-110.1016/S0092-8674(02)00703-1 ↗
70. 10.1038/sj.onc.120993710.1038/sj.onc.1209937 ↗
71. 10.1038/ncprheum068110.1038/ncprheum0681 ↗
72. 10.1038/nature0292410.1038/nature02924 ↗
73. 10.1016/S0955-0674(98)80149-X10.1016/S0955-0674(98)80149-X ↗
74. 10.1016/j.ccr.2005.10.01410.1016/j.ccr.2005.10.014 ↗
75. 10.1007/s13277-016-4854-z10.1007/s13277-016-4854-z ↗
76. 10.1038/ncb123610.1038/ncb1236 ↗
77. Yarza R · Front Pharmacol · 2015 · 6
78. 10.1152/ajpgi.00031.200610.1152/ajpgi.00031.2006 ↗
79. 10.1038/cddis.2015.12010.1038/cddis.2015.120 ↗
80. 10.2147/OTT.S10168710.2147/OTT.S101687 ↗
81. 10.1038/mtna.2015.2310.1038/mtna.2015.23 ↗
82. 10.1016/j.gene.2013.12.01910.1016/j.gene.2013.12.019 ↗
83. 10.1038/nrg296810.1038/nrg2968 ↗
84. 10.1038/nrg200610.1038/nrg2006 ↗
85. 10.1128/MMBR.67.4.657-685.200310.1128/MMBR.67.4.657-685.2003 ↗
86. 10.1200/JCO.2013.55.037610.1200/JCO.2013.55.0376 ↗
87. 10.1158/2159-8290.CD-12-042910.1158/2159-8290.CD-12-0429 ↗
88. 10.1038/gt.2011.7910.1038/gt.2011.79 ↗
89. Momtazi AA, Shahabipour F, Khatibi S, et al. Curcumin as a MicroRNA regulator in cancer: a review. Rev Physiol Biochem Pharmacol. 2016;171:1–138.10.1007/112_2016_3 ↗
90. 10.1073/pnas.091218610710.1073/pnas.0912186107 ↗
91. 10.1038/mt.2012.10710.1038/mt.2012.107 ↗
92. 10.1111/liv.1269810.1111/liv.12698 ↗
93. 10.1007/978-3-540-78709-910.1007/978-3-540-78709-9 ↗
94. 10.1056/NEJMoa160924310.1056/NEJMoa1609243 ↗
95. 10.1016/j.ymthe.2006.01.00110.1016/j.ymthe.2006.01.001 ↗
96. 10.1053/j.gastro.2005.03.00110.1053/j.gastro.2005.03.001 ↗
97. 10.3748/wjg.v20.i2.33310.3748/wjg.v20.i2.333 ↗
98. Salarini R · Curr Cancer Drug Targets · 2015
99. 10.1186/1476-4598-12-11410.1186/1476-4598-12-114 ↗
100. 10.1002/hep.2447110.1002/hep.24471 ↗